CASC9 Potentiates Gemcitabine Resistance in Pancreatic Cancer by Reciprocally Activating NRF2 and the NF-κB Signaling Pathway

Researchers discovered that gemcitabine upregulated the expression of cancer susceptibility candidate 9 (CASC9) in a dose-dependent manner, partially via induction of reactive oxygen species, whereas inhibition of CASC9 expression enhanced gemcitabine-induced oxidative stress and apoptosis in pancreatic cancer cells.